or Try an Advanced Search...

    Technical Analysis for NKGN - NKGen Biotech, Inc.

    Grade Last Price % Change Price Change
    F 1.35 4.65% 0.06
    NKGN closed up 4.65 percent on Wednesday, May 8, 2024, on 1 percent of normal volume.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical NKGN trend table...
    Date Alert Name Type % Chg
    Narrow Range Bar Range Contraction 0.00%
    Outside Day Range Expansion 0.00%
    Wide Bands Range Expansion 0.00%
    MACD Bearish Signal Line Cross Bearish 4.65%
    NR7 Range Contraction 4.65%
    Narrow Range Bar Range Contraction 4.65%
    Wide Bands Range Expansion 4.65%
    Fell Below 20 DMA Bearish 0.75%
    Inside Day Range Contraction 0.75%
    Wide Bands Range Expansion 0.75%
    Older End-of-Day Signals for NKGN ...

       Recent Intraday Alerts

    Alert Time
    Rose Above Previous Day's High about 21 hours ago
    Outside Day about 21 hours ago
    Up 5% about 21 hours ago
    Up 3% about 21 hours ago
    Fell Below Previous Day's Low about 21 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    NKGN Chart by TradingView
    Basic chart:

    Profile

    • Earnings date: Unknown
    NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Immune System Stem Cell Cell Therapy Cell Biology Natural Killer Cell Lymphocytes

    Is NKGN a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 29 NKGen Biotech Announces FDA Clearance of Investigational New Drug (IND) Application for SNK01 NK Cell Therapy in Parkinson’s Disease
    Apr 25 NKGen Biotech Presents Updated NK Cell Therapy Data for Neurodegenerative Disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development Summit
    Apr 24 NKGen Biotech Announces Upcoming Publication at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
    Apr 18 NKGen Biotech Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development Summit
    Apr 11 NKGen Biotech rises 14% on receiving $5M funding for clinical programs
    Apr 11 NKGen Biotech Secures Additional Financing of $5 Million to Continue Advancing Its Clinical Programs
    Mar 25 NKGen releases additional phase 1 data on Alzheimer's candidate
    Mar 25 NKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer’s Disease at the Tau2024 Global Conference
    Mar 4 NKGen Biotech Announces Upcoming Presentation on SNK01 in Alzheimer’s Disease at the Tau2024 Global Conference
    Feb 7 Passage of the Amendment to the Advanced Regenerative Biotech Act a Positive Catalyst for Korean and Japanese Cell Therapy Companies
    See more NKGN news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 12.88
    52 Week Low 0.7802
    Average Volume 4,480,336
    200-Day Moving Average 4.23
    50-Day Moving Average 1.57
    20-Day Moving Average 1.39
    10-Day Moving Average 1.49
    Average True Range 0.26
    RSI (14) 46.52
    ADX 19.44
    +DI 21.38
    -DI 18.88
    Chandelier Exit (Long, 3 ATRs) 1.33
    Chandelier Exit (Short, 3 ATRs) 1.60
    Upper Bollinger Bands 1.93
    Lower Bollinger Band 0.86
    Percent B (%b) 0.46
    BandWidth 76.25
    MACD Line -0.05
    MACD Signal Line -0.04
    MACD Histogram -0.0086
    Fundamentals Value
    Market Cap 29.55 Million
    Num Shares 21.9 Million
    EPS -2.57
    Price-to-Earnings (P/E) Ratio -0.53
    Price-to-Sales 0.00
    Price-to-Book 0.00
    Dividend 0.00
    Dividend Yield 0.00%
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.49
    Resistance 3 (R3) 1.47 1.42 1.46
    Resistance 2 (R2) 1.42 1.38 1.42 1.45
    Resistance 1 (R1) 1.38 1.36 1.40 1.40 1.45
    Pivot Point 1.33 1.33 1.34 1.33 1.33
    Support 1 (S1) 1.29 1.29 1.31 1.31 1.25
    Support 2 (S2) 1.24 1.27 1.24 1.25
    Support 3 (S3) 1.20 1.24 1.24
    Support 4 (S4) 1.22